Today's Research Reports on Stocks to Watch: Kite Pharma and Novavax
NEW YORK, NY / ACCESSWIRE / June 8, 2017 / Both Kite Pharma and Novavax Inc. were big winners on the NASDAQ in Wednesday trading after the companies released positive trial results. Kite Pharma's shares soared on positive results for its leukemia drug KTE-C-19 while Novavax gained after publishing full results from its RSV F vaccine mid-stage clinical trial.
RDI Initiates Coverage on:
Kite Pharma, Inc.
https://ub.rdinvesting.com/news/?ticker=KITE
Novavax, Inc.
https://ub.rdinvesting.com/news/?ticker=NVAX
Kite Pharma, Inc.'s shares closed up 7.12% on Wednesday. On Tuesday the clinical-stage biopharmaceutical company had announced positive results from its phase I trial ZUMA-3, on its lead candidate KTE-C19. The leukemia drug was used in the trial on adults with "high burden relapsed/refractory acute lymphoblastic leukemia." The results showed that the Phase 1 study on the drug had 73% of patients experience complete remission, including patients who were with incomplete or partial recovery of bone marrow. No patient tested positive for minimal residual disease either. Executive Vice President of Research and Development and CMO for Kite, David Chang, stated, "We are encouraged by the results from the ZUMA-3 trial to date in this extremely difficult-to-treat patient population. Before launching a pivotal Phase 2 study, we plan to optimize the cell dose of this potentially life-saving therapy for patients with significant unmet need." The company is already focused on the second phase of the ZUMA-3 trial and has plans to start phase 2 sometime this year.
Access RDI's Kite Pharma Research Report at:
https://ub.rdinvesting.com/news/?ticker=KITE
Novavax, Inc.'s shares closed up 3.92% yesterday on trading volume more than twice as large as usual. The stock even saw gains as high as 6% just in pre-market trading after traders learned that the company had published full results for a mid-stage clinical trial for its RSV F vaccine. The results were published in the medical journal Vaccine and were from the company's phase 3 trial that had enrolled 720 women between 18 and 35 years of age. It's been three years since early results were posted back in the spring of 2014. RSV F vaccine is meant to protect babies from severe lower respiratory tract infections through maternal vaccination. The full results showed that with the vaccine, there was around a 52% reduction in recent respiratory syncytial virus (RSV) infection which lower respiratory tract infections are commonly caused from. President of Research and Development Dr. Gregory Glenn stated, "While it was not the primary endpoint in the trial, the Western Blot data suggest the potential to protect both the pregnant mothers and their infants from RSV disease."
Access RDI's Novavax Research Report at:
https://ub.rdinvesting.com/news/?ticker=NVAX
Our Actionable Research on Kite Pharma, Inc. (NASDAQ: KITE) and Novavax, Inc. (NASDAQ: NVAX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
